You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages
|
|---|---|
| Published in |
Farmacia Hospitalaria, September 2018
|
| DOI | 10.7399/fh.10917 |
| Pubmed ID | |
| Authors |
Juan Carlos Del Río-Valencia, Rocío Asensi-Díez, Lorenzo Villalobos-Torres, Ana Clopés-Estela, M ª Dolores Fraga-Fuentes |
| Abstract |
The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma. The data were analyzed following the recommendations contained in the MADRE program of the GENESIS-SEFH report model. Progression free survival and overall survival results published in the pivotal clinical trial; Tap, WD. et al. (2016) were improvement of 2.5 months in median progression free survival (primary endpoint) HR = 0.672; IC95% (0.442-1.021) and gain of 11.8 months in median OS (secondary endpoint) HR = 0.463; IC95% (0.301-0.710). A cost-effectiveness analyses was performed considering 2 scenarios; scenario 1: with use of whole vials and scenario 2: use of whole vials and associating non-pharmacological costs (day hospital visits, mucositis, neutropenia and dexrazoxane use). In both cases we considered the cost of drugs and the efficacy data of the pivotal clinical trial. In Scenario 1, we would have an Incremental-Cost-Effectiveness-Ratio of €28,443.81/month of progression-free survival and €72,560.74 per year of life gained and in scenario 2 we would have an incremental-cost-effectivenessratio of €30,879.79/ progression-free survival and €78,774.99/ year of life gained. The budgetary impact of this drug would range from €61,759.592 to €92,639.388 estimated to be 800 to 1,200 patients likely to receive treatment in Spain. Olaratumab is a drug that provides a significant benefit in overall survival but not in progression free survival. To be used in soft tissue sarcoma and to be cost-effective, the acquisition cost of the 500 mg vial should be between €101.91 and €506.54 and that of the 190 mg vial between €39.31 and €195.37. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 55% |
| Unknown | 5 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Practitioners (doctors, other healthcare professionals) | 2 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 33% |
| Student > Master | 2 | 17% |
| Other | 1 | 8% |
| Researcher | 1 | 8% |
| Student > Postgraduate | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 3 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 17% |
| Business, Management and Accounting | 2 | 17% |
| Medicine and Dentistry | 2 | 17% |
| Computer Science | 1 | 8% |
| Agricultural and Biological Sciences | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2018.
All research outputs
#6,309,020
of 25,608,265 outputs
Outputs from Farmacia Hospitalaria
#50
of 375 outputs
Outputs of similar age
#101,030
of 346,382 outputs
Outputs of similar age from Farmacia Hospitalaria
#2
of 5 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 375 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,382 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.